美国药厂吉利德科学季绩胜预期 受瑞德西韦销售带动
美国药厂吉利德科学(Gilead Sciences)(GILD.US)第四季经调整後每股盈利为2.19美元,高於市场预期的2.15美元。收入上升26%至74.2亿美元,同样胜预期,主要由於抗病毒药物瑞德西韦(Remdesivir)获准用於治疗感染新冠病毒的患者。
吉利德科学表示,在疫情影响下看病的人数有所减少,令治安丙型肝炎及爱滋病的药品需求下降,但预计市场将从今年第二季开始逐步恢复。
吉利德科学预计今年调整後每股盈利中位数为7.1美元,收入中位数为244亿美元,两者皆高於市场预期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.